Efficacy and safety of nab-paclitaxel in metastatic gastric cancer: a meta-analysis

被引：0

作者：

Ahmad, Suhana ^{[1
]}

Lambuk, Lidawani ^{[1
]}

Ahmed, Naveed ^{[2
]}

Mussa, Ali ^{[3
,4
]}

Tee, Vincent ^{[5
]}

Idris, Ros Akmal Mohd ^{[1
]}

Sahran, Nur Fazimah ^{[5
]}

Chan, Yean Yean ^{[2
]}

Hassan, Rosline ^{[3
]}

Lee, Yeong Yeh ^{[5
,6
]}

Mohamud, Rohimah ^{[1
]}

机构：

[1] Univ Sains Malaysia, Sch Med Sci, Dept Immunol, Kubang Kerian 16150, Kelantan, Malaysia

[2] Univ Sains Malaysia, Sch Med Sci, Dept Med Microbiol & Parasitol, Kubang Kerian 16150, Kelantan, Malaysia

[3] Univ Sains Malaysia, Sch Med Sci, Dept Haematol, Kubang Kerian 16150, Kelantan, Malaysia

[4] Omdurman Islamic Univ, Dept Biol, Omdurman 14415, Sudan

[5] Univ Sains Malaysia, Sch Med Sci, Dept Internal Med, Kubang Kerian 16150, Kelantan, Malaysia

[6] Univ Sains Malaysia, Hosp Univ Sains Malaysia, GI Funct & Motil Unit, Kubang Kerian 16150, Kelantan, Malaysia

来源：

NANOMEDICINE | 2023年 / 18卷 / 24期

关键词：

chemotherapy; nanomedicine; nanoparticle; response rate survival; ALBUMIN-BOUND PACLITAXEL; SOLVENT-BASED PACLITAXEL; PHASE-II; CHEMOTHERAPY; RAMUCIRUMAB; COMBINATION;

D O I：

10.2217/nnm-2022-0300

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Background: Nab-paclitaxel is formulated to address several limitations of paclitaxel. Methods: A systematic review was done of several databases and a meta-analysis with a random-effects model was conducted to assess the efficacy and safety of nab-paclitaxel in metastatic gastric cancer (MGC). Results: Included studies revealed that nab-paclitaxel provides a 30.4% overall response rate and 65.7% disease control rate in MGC patients. The overall survival was 9.65 months and progression-free survival was 4.48 months, associated with the treatment line and regimen. The highest incidence of grade 3 and higher treatment-related adverse events was for neutropenia (29.9%). Conclusion: Nab-paclitaxel provides better disease response and longer survival with manageable side effects in MGC compared with paclitaxel. A systematic review and meta-analysis estimates the efficacy and safety of nab-paclitaxel in metastatic gastric cancer.

引用

页码：1733 / 1744

页数：12

共 50 条

[1] Efficacy and safety of Nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer
Filipazzi, V.
Dalu, D.
Isabella, L.
Tosca, N.
Ferrario, S.
Gambaro, A.
Somma, L.
Fasola, C.
Pellegrini, I.
Bombonati, G.
Curcio, R.
Damiani, E.
Cattaneo, M. T.
ANNALS OF ONCOLOGY, 2017, 28
[2] EFFICACY AND SAFETY OF NAB-PACLITAXEL IN COMBINATION WITH GEMCITABINE FOR METASTATIC PANCREATIC CANCER
You, Min Su
Ryu, Ji Kon
Kang, Jinwoo
Choi, Jin Ho
Choi, Young Hoon
Huh, Gunn
Paik, Woo Hyun
Lee, Sang Hyub
Kim, Yong-Tae
GASTROENTEROLOGY, 2018, 154 (06) : S285 - S285
[3] Combined atezolizumab and nab-paclitaxel in the treatment of triple negative breast cancer: a meta-analysis on their efficacy and safety
Vishnu, K. Sharmni
Win, Thin Thin
Aye, Saint Nway
Basavaraj, Arun Kumar
BMC CANCER, 2022, 22 (01)
[4] Combined atezolizumab and nab-paclitaxel in the treatment of triple negative breast cancer: a meta-analysis on their efficacy and safety
K. Sharmni Vishnu
Thin Thin Win
Saint Nway Aye
Arun Kumar Basavaraj
BMC Cancer, 22
[5] Role of nab-paclitaxel in metastatic breast cancer: a meta-analysis of randomized clinical trials
Liu, Yun
Ye, Guoxin
Yan, Dali
Zhang, Lei
Fan, Fan
Feng, Jifeng
ONCOTARGET, 2017, 8 (42) : 72950 - 72958
[6] Initial Experience with Nab-Paclitaxel for Patients with Advanced Gastric Cancer: Safety and Efficacy
Kanazawa, Yoshikazu
Fujita, Itsuo
Kakinuma, Diasuke
Arai, Hiroki
Matsuno, Kunihiko
Shimoda, Tomohiro
Ko, Kazuhide
Kato, Shunji
Uchida, Eiji
ANTICANCER RESEARCH, 2017, 37 (05) : 2715 - 2720
[7] Efficacy and safety of nab-paclitaxel plus platinum in non-small cell lung cancer: a meta-analysis
Tan, Tianying
Li, Shuangshuang
Hu, Wenting
Yue, Tinghui
Zeng, Qi
Zeng, Xingling
Chen, Xiaochao
Zhao, Xiangdong
Xiao, Tianbao
FRONTIERS IN MEDICINE, 2023, 10
[8] A systematic review and meta-analysis of nab-paclitaxel mono-chemotherapy for metastatic breast cancer
Haili Lu
Siluo Zha
Wei Zhang
Qiang Wang
Daozhen Jiang
Xinyun Xu
Xiangmin Zheng
Ming Qiu
Chengxiang Shan
BMC Cancer, 21
[9] A systematic review and meta-analysis of nab-paclitaxel mono-chemotherapy for metastatic breast cancer
Lu, Haili
Zha, Siluo
Zhang, Wei
Wang, Qiang
Jiang, Daozhen
Xu, Xinyun
Zheng, Xiangmin
Qiu, Ming
Shan, Chengxiang
BMC CANCER, 2021, 21 (01)
[10] Clinical efficacy of nab-paclitaxel in patients with metastatic pancreatic cancer
De Luca, Rossella
Blasi, Livio
Alu, Massimiliano
Gristina, Valerio
Cicero, Giuseppe
DRUG DESIGN DEVELOPMENT AND THERAPY, 2018, 12 : 1769 - 1775

← 1 2 3 4 5 →